PL2496568T3 - Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne - Google Patents
Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczneInfo
- Publication number
- PL2496568T3 PL2496568T3 PL10825954T PL10825954T PL2496568T3 PL 2496568 T3 PL2496568 T3 PL 2496568T3 PL 10825954 T PL10825954 T PL 10825954T PL 10825954 T PL10825954 T PL 10825954T PL 2496568 T3 PL2496568 T3 PL 2496568T3
- Authority
- PL
- Poland
- Prior art keywords
- substituteddihydroisoindolinone
- dioxopiperidine
- polymorph
- pharmaceutical compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102103923A CN101696205B (zh) | 2009-11-02 | 2009-11-02 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| EP10825954.0A EP2496568B1 (en) | 2009-11-02 | 2010-11-02 | Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof |
| PCT/CN2010/001751 WO2011050590A1 (en) | 2009-11-02 | 2010-11-02 | Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2496568T3 true PL2496568T3 (pl) | 2017-12-29 |
Family
ID=42141345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10825954T PL2496568T3 (pl) | 2009-11-02 | 2010-11-02 | Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9101620B2 (pl) |
| EP (1) | EP2496568B1 (pl) |
| JP (1) | JP2013509357A (pl) |
| KR (1) | KR20130026414A (pl) |
| CN (1) | CN101696205B (pl) |
| AU (1) | AU2010312224B2 (pl) |
| ES (1) | ES2634666T3 (pl) |
| PL (1) | PL2496568T3 (pl) |
| WO (1) | WO2011050590A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| CN104072476B (zh) * | 2013-03-27 | 2018-08-21 | 江苏豪森药业集团有限公司 | 泊马度胺晶型及其制备方法和用途 |
| CN104016966A (zh) * | 2014-01-30 | 2014-09-03 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| PT925294E (pt) | 1996-07-24 | 2003-04-30 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimidas e -1-oxoisoindolinas substituidas e metodo de reducao dos niveis de tnf-alfa |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| JP2005536189A (ja) | 2002-04-12 | 2005-12-02 | セルジーン・コーポレーション | 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法 |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| KR100822149B1 (ko) | 2002-05-17 | 2008-04-15 | 셀진 코포레이션 | 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물 |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| NZ540028A (en) | 2002-10-24 | 2009-07-31 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| TWI310312B (en) | 2002-10-31 | 2009-06-01 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| CN1822834A (zh) | 2003-05-15 | 2006-08-23 | 细胞基因公司 | 使用免疫调节化合物治疗和处理癌症及其它疾病的方法和组合物 |
| UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| CA2547570A1 (en) | 2003-12-02 | 2005-06-23 | Celgene Corporation | 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| KR101224262B1 (ko) | 2004-03-22 | 2013-01-21 | 셀진 코포레이션 | 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법 |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| MXPA06011798A (es) | 2004-04-14 | 2007-01-16 | Celgene Corp | Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos. |
| BRPI0510110A (pt) | 2004-04-23 | 2007-09-25 | Celgene Corp | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica |
| MXPA06012648A (es) | 2004-05-05 | 2007-02-14 | Celgene Corp | Metodo de utilizacion y composiciones que comprenden compuestos inmunomodulatorios para el tratamiento y manejo de enfermedades mieloproliferativas. |
| ES2437592T3 (es) * | 2004-09-03 | 2014-01-13 | Celgene Corporation | Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas |
| WO2006053160A2 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| KR20070086601A (ko) | 2004-11-23 | 2007-08-27 | 셀진 코포레이션 | 중추신경계 손상의 치료 및 관리를 위해 면역조절 화합물을사용하는 방법 및 조성물 |
| AU2005311888A1 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| CN101531653B (zh) | 2008-03-13 | 2014-07-09 | 峡江和美药业有限公司 | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 |
| TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法 |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
-
2009
- 2009-11-02 CN CN2009102103923A patent/CN101696205B/zh active Active
-
2010
- 2010-11-02 PL PL10825954T patent/PL2496568T3/pl unknown
- 2010-11-02 US US13/501,437 patent/US9101620B2/en active Active
- 2010-11-02 ES ES10825954.0T patent/ES2634666T3/es active Active
- 2010-11-02 EP EP10825954.0A patent/EP2496568B1/en active Active
- 2010-11-02 WO PCT/CN2010/001751 patent/WO2011050590A1/en not_active Ceased
- 2010-11-02 JP JP2012535589A patent/JP2013509357A/ja active Pending
- 2010-11-02 AU AU2010312224A patent/AU2010312224B2/en not_active Ceased
- 2010-11-02 KR KR1020127011302A patent/KR20130026414A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN101696205B (zh) | 2011-10-19 |
| EP2496568A1 (en) | 2012-09-12 |
| AU2010312224B2 (en) | 2014-04-10 |
| US9101620B2 (en) | 2015-08-11 |
| WO2011050590A1 (en) | 2011-05-05 |
| JP2013509357A (ja) | 2013-03-14 |
| US20120203005A1 (en) | 2012-08-09 |
| ES2634666T3 (es) | 2017-09-28 |
| KR20130026414A (ko) | 2013-03-13 |
| CN101696205A (zh) | 2010-04-21 |
| EP2496568A4 (en) | 2013-04-24 |
| EP2496568B1 (en) | 2017-04-26 |
| AU2010312224A1 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL214822A0 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| PT2482812T (pt) | Composições farmacêuticas compreendendo bi-1356 e metformina | |
| IL214425A (en) | Converted metastatic heterocyclic compounds, their pharmaceutical preparations and their uses | |
| EP2254555A4 (en) | APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF | |
| EP2395975A4 (en) | ORAL PHARMACEUTICAL COMPOSITION OF DUTASTERIDE | |
| ZA201108292B (en) | New compounds,pharmaceutical composition and methods relating thereto | |
| SI2281822T1 (sl) | Novi derivati dihidroindolona, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo | |
| ZA201107104B (en) | Derivatives of benzothiazines,preparation thereof and application thereof as drugs | |
| PT2504331E (pt) | Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização | |
| IL248077A0 (en) | Formulations, salts and polymers of transnorsertraline and their uses | |
| IL216462A (en) | Pharmaceuticals containing nitrile history and uses | |
| IL213177A0 (en) | Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide | |
| PL2496568T3 (pl) | Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne | |
| ZA201303692B (en) | Diphenyl-amine derivatives:uses,process of synthesis and pharmaceutical compositions | |
| IL211062A0 (en) | Pharmaceutical uses of lanosta-8,24-dien-3-ols | |
| GB201210536D0 (en) | Composition, use and method of preparation thereof | |
| EP2484661A4 (en) | 2,3-DIHYDRO-1H-INDEN-2-YL-UREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| GB0902648D0 (en) | Pharmaceutical compounds and compositions | |
| IL219018A (en) | Radzolid Pharmaceuticals and Uses | |
| EP2626347A4 (en) | DALFAMPRIDINPOLYMORPH AND THE PREPARATION AND USE THEREOF | |
| ZA201105443B (en) | Novel saponin compounds,methods of preparation thereof,use thereof and pharmaceutical compositions | |
| EP2404588A4 (en) | PACKAGING FOR SOLID PHARMACEUTICAL PREPARATION | |
| PL2277511T3 (pl) | Kompozycje farmaceutyczne lewetiracetamu o przedłużonym uwalnianiu | |
| GB0908317D0 (en) | Pharmaceutical compounds and compositions | |
| AP2012006117A0 (en) | Pharmaceutical composition of rifampicin. |